Phase II Trial of Oral Idarubicin in Advanced Non-Small Cell Lung Cancer (NSCLC)

Andrea Ardizzoni Istituto Nazionale per la Ricerca sul Cancro V. le Benedetto XV, 10 16132, Geneva

Paolo Pronzato Istituto Nazionale per la Ricerca sul Cancro V. le Benedetto XV, 10 16132, Geneva

Lazzaro Repetto Istituto Nazionale per la Ricerca sul Cancro V. le Benedetto XV, 10 16132, Geneva

Mario De Palma Divisione dl Broncologia Ospedale S. Martino, Geneva

Luciano Canobbio Istituto Nazionale per la Ricerca sul Cancro V. le Benedetto XV, 10 16132, Geneva

Marcella Gulisano Istituto Nazionale per la Ricerca sul Cancro V. le Benedetto XV, 10 16132, Geneva

Vittorio Fusco Istituto Nazionale per la Ricerca sul Cancro V. le Benedetto XV, 10 16132, Geneva

Riccardo Rosso Istituto Nazionale per la Ricerca sul Cancro V. le Benedetto XV, 10 16132, Geneva

Franco Ganzina Farmitalia Carlo Erba, Via Imbonati, 24, 20159, Milano, Italy

show all

Abstract

The antitumoral activity and toxicity of a new daunorubicin analog (4-demethoxydaunorubicin, IMI30, Idarubicin) was tested in 20 consecutive patients with non-small cell lung cancer mostly pretreated with chemotherapy. The drug was administered orally at a dose of 15 mg/m² for three days every 3-4 weeks. There were no clinical responses. Hematological and nonhematobgical toxicities were mild.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Phase II Trial of Oral Idarubicin in Advanced Non-Small Cell Lung Cancer (NSCLC)

Information for

Open access

Opportunities

Help and information

Phase II Trial of Oral Idarubicin in Advanced Non-Small Cell Lung Cancer (NSCLC)

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature